Developer docs
API playgroundTry for free, no card

Search company profiles

Celemics

Full company profile

uuid003ek4k

Namestring
Celemics
Legal namestring
Celemics, Inc.
Websiteurl
celemics.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Celemics is a Seoul-headquartered, KOSDAQ-listed (kosdaq:331920) biotechnology company founded in 2010 that develops and sells target enrichment panels and associated reagents for next-generation sequencing (NGS) workflows. Its core offering is a catalog of more than 1,000 custom-designed panels — including whole-exome, ready-to-use disease panels (e.g., CancerScreen, CancerMaster, OncoKB Plus), and bespoke designs built on proprietary probe-design, rebalancing, and molecular-barcoding chemistry — used by biopharma R&D groups, contract research organizations, clinical diagnostic laboratories, and academic research centers. Panels are validated across all major sequencing platforms (Illumina, MGI, Thermo Fisher, PacBio, and Oxford Nanopore), and the company layers in modular library-preparation kits, beads, polymerases, and capture-accessory reagents to anchor a full workflow sale.

The company monetizes primarily through direct panel and reagent sales, custom panel design services, and recurring bioinformatics subscriptions for its CAS (Celemics Analysis Service) pipeline, which performs FASTQ-to-variant calling, annotation, and clinical interpretation. A US subsidiary opened in 2024 and a strategic partnership with Strand Life Sciences extend distribution into North America and India, while product launches including the CAS Pathogen platform (2024) and an ONT Adaptive Sampling–compatible Target Enrichment Kit (May 2026) broaden the addressable workflow. The firm employs 51–100 people and has raised modest equity capital through 2026 KOSDAQ secondary offerings, consistent with a small-cap, execution-stage life-science tools company rather than an early-stage venture-backed startup.

Short descriptiontext

Celemics is a Seoul-based, KOSDAQ-listed NGS tools company that designs custom and ready-to-use target enrichment panels, library-prep reagents, and the CAS bioinformatics pipeline for biopharma, CROs, and clinical diagnostic labs globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NGS target enrichment, whole exome sequencing, companion diagnostics development, hybridization probe design, bioinformatics analysis services
Industry5 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Laboratory Analytical Instruments3826
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
NGS Target Enrichment Reagents and Panels
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1NGS Panels and Reagents
TypeOne Time License
Description

Sale of ready-to-use NGS panels, target enrichment kits, customized panels, and modular accessories including library preparation kits, magnetic beads, hybridization enhancers, polymerases, and molecular barcode kits. Products sold directly and through distributors globally.

celemics.com
2Sequencing and Bioinformatics Services
TypeProfessional Services
Description

Celemics Analysis Service (CAS) providing end-to-end bioinformatics analysis from FASTQ to clinical interpretation. Also includes whole exome sequencing service, immune repertoire profiling, and high-throughput genotyping services.

celemics.com
3Custom NGS Assay Development
TypeProfessional Services
Description

End-to-end customized assay development from design to validation, including custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, and optimization for individual experiments.

celemics.com
4Biopharma Solutions and Companion Diagnostics
TypeLicensing Royalties
Description

NGS-based detection and discovery solutions for biopharma, CRO, and drug discovery research fields, including development and commercialization of companion diagnostics.

celemics.com
5White-Label / OEM Products
TypeLicensing Royalties
Description

White-labeled customized products with customer branding and labeling, allowing partners to market and sell Celemics-developed panels under their own brand for business expansion support.

celemics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details1 tier
1NGS Panels and Reagents - quote-based pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed; direct inquiry required via contact form.

celemics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1BTSeq™
Description

Sequencing service offered by Celemics

celemics.com
+6 more records
Core offering1 text field

Celemics designs, manufactures, and supplies hybridization-based Next-Generation Sequencing (NGS) target enrichment panels, custom assay development services, and end-to-end bioinformatics for genomics applications in oncology, inherited disease, biopharma/CRO drug discovery, pathogen surveillance, and agrigenomics. Its offering combines proprietary probe design and rebalancing technologies, molecular barcodes for low-input and cfDNA samples, ready-to-use and customized panels, modular reagents (library prep kits, beads, polymerases), and the Celemics Analysis Service (CAS) bioinformatics pipeline running from FASTQ through clinical interpretation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • WES panel achieves >98% coverage of all exonic regions of major exome panels (37.1 Mb target size)
+6 more records
Product overview1 text field

Celemics is a biotech company specializing in NGS (Next-Generation Sequencing) solutions, offering a comprehensive portfolio of products and services organized around three core pillars: (1) Target Enrichment Products including the Whole Exome Sequencing Panel (WES, 37.1 Mb), NGS Target Enrichment Panel, Customized NGS Panel, and Ready-to-Use NGS Panels; (2) Bioinformatics through Celemics Analysis Service (CAS) providing end-to-end analysis from FASTQ to clinical interpretation; and (3) Modular Accessories including Library Preparation Kit, Double-stranded cDNA Synthesis Kit, Hybridization Enhancer, CeleMag Clean-up Beads, Streptavidin Beads, CeleNM Bead, and CLM Polymerase. The Ready-to-Use NGS Panel platform encompasses sub-brands for Somatic Cancer (CancerScreen, CancerScreen Focus, CancerMaster), Liquid Biopsy, Hereditary Cancer, BioPharma Solutions, BRCA 1/2, Clinical Exome, PharmacoScreen, Respiratory Virus, African Swine Fever Virus, High-Throughput Genotyping, RNA/Methylation/Metagenomic Sequencing, Mitochondrial DNA, and Disease Specific panels. Services include sequencing services, bioinformatics services, biopharma solutions, and custom NGS assay development. All products support multiple sequencing platforms (Illumina, MGI, Thermo Fisher, PacBio, Oxford Nanopore) and integrate with automated liquid handling systems (Hamilton, Bravo, Sciclone).

Product and service26 records
1Whole Exome Sequencing Panel (WES)
CategoryNGS Target Enrichment Panels
Description

Comprehensive whole exome panel covering 37.1 Mb target regions of all major WES panels in the market with >98% coverage, market-leading on-target ratio (>90% on gDNA and FFPE), uniformity (>96% gDNA, >95% FFPE), and up to 12-plex multiplexing, supported by the Celemics Analysis Service (CAS) bioinformatics pipeline. Targeted at clinical labs, research institutions, and biopharma doing comprehensive variant discovery across coding regions.

2NGS Target Enrichment Panel
CategoryNGS Target Enrichment Panels
Description

Hybridization-based target enrichment panel leveraging Celemics' proprietary probe design, rebalancing, and molecular barcode technologies to efficiently capture hard-to-capture regions, GC-rich areas, and challenging samples (damaged DNA/RNA, FFPE, ctDNA) across multiple sequencing platforms. Targeted at genomics labs running custom or research-focused capture assays.

3Customized NGS Panel
CategoryNGS Target Enrichment Panels
Description

End-to-end customized target enrichment panel service including custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, validation, and complete bioinformatics support, with optional white-label/OEM branding for partners. Targeted at biopharma, CROs, and research groups needing tailored assays; over 1,000 such panels have been developed and delivered globally.

4Ready-to-Use NGS Panel
CategoryPre-Validated NGS Panels
Description

Pre-validated hybridization-based NGS panels covering oncology, liquid biopsy, hereditary cancer, BRCA 1/2, clinical exome, disease-specific panels, infectious disease (respiratory virus, ASFV), pharmacogenomics (PharmacoScreen), agrigenomics, RNA, methylation, metagenomic, and mitochondrial DNA sequencing applications, all built on Celemics' proprietary core technologies. Targeted at clinical and research users needing validated, ready-to-ship catalog panels.

5CancerScreen Panels
CategoryPre-Validated NGS Panels — Oncology
Description

Ready-to-use NGS panels for somatic cancer that detect all variant types including SNV, Indel, CNV, rearrangements, MSI, and TMB, offered in Core (13 genes), 50 (54 genes), 100 (99 genes), 400 (407 genes), and Comprehensive (706 genes) configurations. Targeted at molecular pathology and oncology labs needing comprehensive mutation profiling from FFPE or fresh tissue.

6CancerScreen Focus (CDx) Panel
CategoryPre-Validated NGS Panels — Oncology
Description

FDA-focused cancer panel covering major genes with coding exons concerning mutations for FDA-approved therapies, delivered in DNA (22 genes, 73.4 Kb) and RNA (9 genes, 32.1 Kb) configurations. Targeted at labs and biopharma requiring companion-diagnostic-ready content.

7CancerMaster
CategoryPre-Validated NGS Panels — Oncology
Description

Comprehensive somatic cancer panel detecting all variant types and immuno-oncology markers including gene rearrangements across 524 cancer-related and cancer-associated genes in a 2.5 Mb target. Targeted at advanced molecular oncology programs needing broad immuno-oncology and rearrangement profiling.

8Liquid Biopsy Panels
CategoryPre-Validated NGS Panels — Liquid Biopsy
Description

ctDNA-based NGS panels with proprietary molecular barcodes for superior sensitivity in detecting low-frequency variants, available for lung cancer (28 genes, 47 Kb), breast cancer (27 genes, 99 Kb), and colorectal cancer (15 genes, 49 Kb). Targeted at clinical and research liquid biopsy workflows needing sensitive ctDNA variant calling.

9Hereditary Cancer (OncoRisk) Panel
CategoryPre-Validated NGS Panels — Hereditary Cancer
Description

Comprehensive hereditary cancer panel analyzing 31 oncogenes associated with inherited cancer syndromes in a 96 Kb target. Targeted at clinical genetics and hereditary cancer screening programs.

10BRCA 1/2 Panel
CategoryPre-Validated NGS Panels — Hereditary Cancer
Description

Comprehensive BRCA coverage panel targeting BRCA1 and BRCA2 (2 genes, 23 Kb) and covering all variant types (SNVs, indels, large rearrangements). Targeted at clinical labs offering hereditary breast/ovarian cancer testing.

11Clinical Exome
CategoryPre-Validated NGS Panels — Clinical Exome
Description

Clinical exome sequencing panels for comprehensive detection of clinically significant variants, available in Standard (5,516 genes, 13.8 Mb) and Expanded (7,563 genes, 19.6 Mb) versions. Targeted at clinical diagnostics labs focused on inherited disease and rare disease variant detection.

12PharmacoScreen
CategoryPre-Validated NGS Panels — Pharmacogenomics
Description

Pharmacogenomics panel targeting genes associated with drug metabolism, available in Standard (283 genes, 634 Kb), Epilepsy (91 genes, 575.3 Kb), and Anti-Tuberculosis (132 genes, 186.1 Kb) configurations. Targeted at clinical labs, hospitals, and biopharma running pharmacogenomics-informed prescribing.

13Disease Specific Panel
CategoryPre-Validated NGS Panels — Disease Specific
Description

Comprehensive panels for identification of 14–293 disease-related genes in a single NGS reaction with proven clinical usage, with target sizes ranging 37–1,159 Kb. Targeted at rare disease and inherited disorder diagnostic workflows.

14RNA Sequencing Panel
CategoryPre-Validated NGS Panels — RNA Sequencing
Description

Targeted RNA sequencing solution for transcriptome, fusion, and isoform analyses, supported by the Celemics double-stranded cDNA synthesis kit. Targeted at research and translational labs needing validated targeted RNA capture.

15Methylation Sequencing Panel
CategoryPre-Validated NGS Panels — Methylation
Description

Comprehensive DNA methylation sequencing solution with proprietary probes specifically designed for methyl-seq, enabling accurate detection of methylation sites for epigenetics research. Targeted at epigenetics research programs.

16Metagenomic Sequencing Panel
CategoryPre-Validated NGS Panels — Metagenomics
Description

Complete targeted metagenomic sequencing solution with flexible panel design for characterization and differentiation of microbial species and bacterial pathogen detection. Targeted at infectious disease and microbiome research labs.

17Mitochondrial DNA Panel
CategoryPre-Validated NGS Panels — Mitochondrial DNA
Description

High-uniformity, complete-coverage panel for human mitochondrial genome sequencing. Targeted at labs running mtDNA variant detection for inherited disease and population genetics research.

18Respiratory Virus Panel
CategoryPre-Validated NGS Panels — Pathogen
Description

Comprehensive panel for rapid and accurate sequencing and identification of whole genomes of 39 respiratory virus strains in a 706 Kb target. Targeted at public health labs and infectious disease surveillance programs.

19African Swine Fever Virus Panel
CategoryPre-Validated NGS Panels — Pathogen (Animal Health)
Description

Accurate identification of various ASFV strains in a single NGS reaction with species-specific blockers, targeting 26 strains in a 192 Kb target. Targeted at veterinary and animal health surveillance programs.

20High-Throughput Genotyping Panel
CategoryPre-Validated NGS Panels — Agrigenomics
Description

NGS-based target enrichment panel for higher genotyping efficiency and accuracy in plant and animal research, providing a cost-effective solution compared to conventional GBS, PCR, and microarray methods. Targeted at agrigenomics research and breeding programs.

21BioPharma Solutions
CategoryBiopharma and CRO Solutions
Description

End-to-end NGS-based detection and discovery solutions for biopharma companies, CROs, and drug discovery research fields, including companion diagnostics development, clinical trial support, drug discovery research, and pharmacogenomics panels. Targeted at biopharma and CRO drug development programs.

22Celemics Analysis Service (CAS)
CategoryBioinformatics Services
Description

End-to-end bioinformatics pipeline providing primary, secondary (CNV, Large InDel, TMB, MSI detection), and tertiary (variant curation, phenotype association) analysis with a click-to-upload FASTQ workflow and automated clinical interpretation report generation. Targeted at labs needing FASTQ-to-clinical-report processing without third-party bioinformaticians.

23Immune Repertoire Profiling Service
CategorySequencing Services
Description

NGS-based BCR and TCR sequencing service with ultra-sensitivity MRD monitoring detecting MRD as low as 10⁻⁶, using optimized primers to minimize sequencing loss and PCR duplications. Targeted at immuno-oncology research and minimal residual disease studies.

24Whole Exome Sequencing Service
CategorySequencing Services
Description

Full-service WES offering using the Celemics WES panel with complete bioinformatics analysis and clinical interpretation support. Targeted at research and clinical customers needing turnkey exome sequencing without in-house wet-lab or bioinformatics capacity.

25High-Throughput Genotyping Service
CategorySequencing Services
Description

NGS-based target enrichment genotyping service delivering higher efficiency and accuracy than conventional GBS, PCR, and microarray methods for plant and animal research. Targeted at agrigenomics research groups and breeding programs.

26Custom NGS Assay Development
CategoryCustom Assay Development Services
Description

Tailored-fit assay development service covering custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, and validation runs to optimize individual experiments. Targeted at research and clinical customers needing non-standard or novel NGS assays.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-24
Description

Strategic partnership integrating Celemics NGS target enrichment kit and bioinformatics pipeline with Strand Life Sciences' StrandOmics tertiary analysis platform. Provides seamless sample-to-report solution ensuring clinical-grade data compliance and guaranteed data residency for customers across Europe and Asia. Over 2.5 years of collaboration with Strand analyzing clinical cases including Whole Exome Sequencing for rare diseases, Hereditary Cancer Test, and OncoRisk Test for germline cancer with a 3-day turnaround time. Strand's expert variant scientists provided interpretation and review of over 30,000 variants.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Eurofins Genomics operates one of the largest global genomics service networks, offering NGS panels, custom sequencing, and bioinformatics with strong European footprint. Eurofins competes with Celemics across clinical exome, rare disease, and biopharma sequencing services, particularly in European markets.

TypeDirect peer
Description

IDT, owned by Danaher, is a leading provider of NGS target enrichment solutions including xGen hybridization capture panels and Lockdown probes. IDT directly competes with Celemics in custom panel development and serves the same biopharma, clinical, and research customer base with overlapping catalog offerings.

TypeBroad incumbent
Description

Agilent's SureSelect target enrichment platform is the dominant hybridization capture chemistry in clinical and translational genomics. Agilent competes broadly with Celemics across whole-exome, custom panels, and biopharma services, with significantly greater installed base and clinical validation footprint.

TypeRegional player
Description

Azenta/GENEWIZ is a major genomics services provider with global lab operations, offering NGS services including custom panels, WES, and bioinformatics. Azenta competes with Celemics' sequencing services and CAS bioinformatics offerings, particularly for biopharma customers seeking outsourcing alternatives to in-house capture workflows.

TypeEmerging player
Description

BGI/MGI offers an integrated sequencing platform (DNBSEQ) along with capture chemistry and panels, and Celemics explicitly validates compatibility with MGI platforms. As MGI expands internationally, it represents both a partner opportunity and a competitive threat in the broader NGS ecosystem.

TypeBroad incumbent
Description

Illumina offers TruSeq, TruSight, and Illumina Exome panels as part of its sequencing platform ecosystem. While Illumina's capture chemistry is more limited than specialists, its bundling with the dominant sequencing platform creates competitive pressure on pure-play capture providers like Celemics, particularly in clinical genomics.

7Roche (NimbleGen)
TypeBroad incumbent
Description

Roche's NimbleGen SeqCap capture chemistry is a legacy target enrichment platform with a substantial installed base in academic and clinical genomics. Roche competes with Celemics in whole-exome and custom capture, particularly for translational and CDx applications tied to Roche's diagnostic franchise.

TypeDirect peer
Description

Twist Bioscience is the closest direct competitor to Celemics, offering DNA synthesis platforms and a comprehensive portfolio of NGS target enrichment panels and custom panels. Both companies compete in hybridization-based capture chemistry, custom panel development, and biopharma/CRO services, with Twist also pursuing the white-label/OEM model.

TypeOthers
Description

PacBio is a long-read sequencing platform provider with which Celemics has validated compatibility via instrument-specific blockers and assay optimization. PacBio represents both a partner (for Celemics' capture chemistry on HiFi platforms) and an indirect competitor as whole-genome HiFi sequencing reduces reliance on target enrichment.

TypeBroad incumbent
Description

Bio-Techne's ProteinSimple and ExoDx brands include genomics-adjacent reagent and assay solutions. While Bio-Techne is more focused on proteomics, its life science tools portfolio competes for the same biopharma R&D budget and provides an alternative for reagent procurement in workflows adjacent to Celemics' products.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celemics

NGS Target Enrichment Reagents and Panelscelemics.com

Celemics is a Seoul-based, KOSDAQ-listed NGS tools company that designs custom and ready-to-use target enrichment panels, library-prep reagents, and the CAS bioinformatics pipeline for biopharma, CROs, and clinical diagnostic labs globally.

What Celemics does

Celemics is a Seoul-headquartered, KOSDAQ-listed (kosdaq:331920) biotechnology company founded in 2010 that develops and sells target enrichment panels and associated reagents for next-generation sequencing (NGS) workflows. Its core offering is a catalog of more than 1,000 custom-designed panels — including whole-exome, ready-to-use disease panels (e.g., CancerScreen, CancerMaster, OncoKB Plus), and bespoke designs built on proprietary probe-design, rebalancing, and molecular-barcoding chemistry — used by biopharma R&D groups, contract research organizations, clinical diagnostic laboratories, and academic research centers. Panels are validated across all major sequencing platforms (Illumina, MGI, Thermo Fisher, PacBio, and Oxford Nanopore), and the company layers in modular library-preparation kits, beads, polymerases, and capture-accessory reagents to anchor a full workflow sale.

The company monetizes primarily through direct panel and reagent sales, custom panel design services, and recurring bioinformatics subscriptions for its CAS (Celemics Analysis Service) pipeline, which performs FASTQ-to-variant calling, annotation, and clinical interpretation. A US subsidiary opened in 2024 and a strategic partnership with Strand Life Sciences extend distribution into North America and India, while product launches including the CAS Pathogen platform (2024) and an ONT Adaptive Sampling–compatible Target Enrichment Kit (May 2026) broaden the addressable workflow. The firm employs 51–100 people and has raised modest equity capital through 2026 KOSDAQ secondary offerings, consistent with a small-cap, execution-stage life-science tools company rather than an early-stage venture-backed startup.

Celemics firmographics

Firmographics
Name
Celemics
Legal name
Celemics, Inc.
Website
https://celemics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Celemics is a Seoul-based, KOSDAQ-listed NGS tools company that designs custom and ready-to-use target enrichment panels, library-prep reagents, and the CAS bioinformatics pipeline for biopharma, CROs, and clinical diagnostic labs globally.
Ownership category
akta.pro rank

Celemics industry classification

Industry
Product category
NGS Target Enrichment Reagents and Panels
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • NGS target enrichment
  • Whole exome sequencing
  • Companion diagnostics development
  • Hybridization probe design
  • Bioinformatics analysis services

Where Celemics is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Celemics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. NGS Panels and Reagents: Sale of ready-to-use NGS panels, target enrichment kits, customized panels, and modular accessories including library preparation kits, magnetic beads, hybridization enhancers, polymerases, and molecular barcode kits. Products sold directly and through distributors globally.
  2. Sequencing and Bioinformatics Services: Celemics Analysis Service (CAS) providing end-to-end bioinformatics analysis from FASTQ to clinical interpretation. Also includes whole exome sequencing service, immune repertoire profiling, and high-throughput genotyping services.
  3. Custom NGS Assay Development: End-to-end customized assay development from design to validation, including custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, and optimization for individual experiments.
  4. Biopharma Solutions and Companion Diagnostics: NGS-based detection and discovery solutions for biopharma, CRO, and drug discovery research fields, including development and commercialization of companion diagnostics.
  5. White-Label / OEM Products: White-labeled customized products with customer branding and labeling, allowing partners to market and sell Celemics-developed panels under their own brand for business expansion support.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNGS Panels and Reagents - quote-based pricing

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Celemics product offering

Product offering

Core offering

Celemics designs, manufactures, and supplies hybridization-based Next-Generation Sequencing (NGS) target enrichment panels, custom assay development services, and end-to-end bioinformatics for genomics applications in oncology, inherited disease, biopharma/CRO drug discovery, pathogen surveillance, and agrigenomics. Its offering combines proprietary probe design and rebalancing technologies, molecular barcodes for low-input and cfDNA samples, ready-to-use and customized panels, modular reagents (library prep kits, beads, polymerases), and the Celemics Analysis Service (CAS) bioinformatics pipeline running from FASTQ through clinical interpretation.

Product overview

Celemics is a biotech company specializing in NGS (Next-Generation Sequencing) solutions, offering a comprehensive portfolio of products and services organized around three core pillars: (1) Target Enrichment Products including the Whole Exome Sequencing Panel (WES, 37.1 Mb), NGS Target Enrichment Panel, Customized NGS Panel, and Ready-to-Use NGS Panels; (2) Bioinformatics through Celemics Analysis Service (CAS) providing end-to-end analysis from FASTQ to clinical interpretation; and (3) Modular Accessories including Library Preparation Kit, Double-stranded cDNA Synthesis Kit, Hybridization Enhancer, CeleMag Clean-up Beads, Streptavidin Beads, CeleNM Bead, and CLM Polymerase. The Ready-to-Use NGS Panel platform encompasses sub-brands for Somatic Cancer (CancerScreen, CancerScreen Focus, CancerMaster), Liquid Biopsy, Hereditary Cancer, BioPharma Solutions, BRCA 1/2, Clinical Exome, PharmacoScreen, Respiratory Virus, African Swine Fever Virus, High-Throughput Genotyping, RNA/Methylation/Metagenomic Sequencing, Mitochondrial DNA, and Disease Specific panels. Services include sequencing services, bioinformatics services, biopharma solutions, and custom NGS assay development. All products support multiple sequencing platforms (Illumina, MGI, Thermo Fisher, PacBio, Oxford Nanopore) and integrate with automated liquid handling systems (Hamilton, Bravo, Sciclone).

Differentiator

Problem solved

Functional benefit

Brands

  • BTSeq™: Sequencing service offered by Celemics
  • CancerScreen
  • CancerMaster
  • Celemics Analysis Service (CAS)
  • CeleMag™ Clean-up Beads
  • CeleNM™ Bead
  • CLM Polymerase

Products and services

  • Whole Exome Sequencing Panel (WES) Comprehensive whole exome panel covering 37.1 Mb target regions of all major WES panels in the market with >98% coverage, market-leading on-target ratio (>90% on gDNA and FFPE), uniformity (>96% gDNA, >95% FFPE), and up to 12-plex multiplexing, supported by the Celemics Analysis Service (CAS) bioinformatics pipeline. Targeted at clinical labs, research institutions, and biopharma doing comprehensive variant discovery across coding regions.
  • NGS Target Enrichment Panel Hybridization-based target enrichment panel leveraging Celemics' proprietary probe design, rebalancing, and molecular barcode technologies to efficiently capture hard-to-capture regions, GC-rich areas, and challenging samples (damaged DNA/RNA, FFPE, ctDNA) across multiple sequencing platforms. Targeted at genomics labs running custom or research-focused capture assays.
  • Customized NGS Panel End-to-end customized target enrichment panel service including custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, validation, and complete bioinformatics support, with optional white-label/OEM branding for partners. Targeted at biopharma, CROs, and research groups needing tailored assays; over 1,000 such panels have been developed and delivered globally.
  • Ready-to-Use NGS Panel Pre-validated hybridization-based NGS panels covering oncology, liquid biopsy, hereditary cancer, BRCA 1/2, clinical exome, disease-specific panels, infectious disease (respiratory virus, ASFV), pharmacogenomics (PharmacoScreen), agrigenomics, RNA, methylation, metagenomic, and mitochondrial DNA sequencing applications, all built on Celemics' proprietary core technologies. Targeted at clinical and research users needing validated, ready-to-ship catalog panels.
  • CancerScreen Panels Ready-to-use NGS panels for somatic cancer that detect all variant types including SNV, Indel, CNV, rearrangements, MSI, and TMB, offered in Core (13 genes), 50 (54 genes), 100 (99 genes), 400 (407 genes), and Comprehensive (706 genes) configurations. Targeted at molecular pathology and oncology labs needing comprehensive mutation profiling from FFPE or fresh tissue.
  • CancerScreen Focus (CDx) Panel FDA-focused cancer panel covering major genes with coding exons concerning mutations for FDA-approved therapies, delivered in DNA (22 genes, 73.4 Kb) and RNA (9 genes, 32.1 Kb) configurations. Targeted at labs and biopharma requiring companion-diagnostic-ready content.
  • CancerMaster Comprehensive somatic cancer panel detecting all variant types and immuno-oncology markers including gene rearrangements across 524 cancer-related and cancer-associated genes in a 2.5 Mb target. Targeted at advanced molecular oncology programs needing broad immuno-oncology and rearrangement profiling.
  • Liquid Biopsy Panels ctDNA-based NGS panels with proprietary molecular barcodes for superior sensitivity in detecting low-frequency variants, available for lung cancer (28 genes, 47 Kb), breast cancer (27 genes, 99 Kb), and colorectal cancer (15 genes, 49 Kb). Targeted at clinical and research liquid biopsy workflows needing sensitive ctDNA variant calling.
  • Hereditary Cancer (OncoRisk) Panel Comprehensive hereditary cancer panel analyzing 31 oncogenes associated with inherited cancer syndromes in a 96 Kb target. Targeted at clinical genetics and hereditary cancer screening programs.
  • BRCA 1/2 Panel Comprehensive BRCA coverage panel targeting BRCA1 and BRCA2 (2 genes, 23 Kb) and covering all variant types (SNVs, indels, large rearrangements). Targeted at clinical labs offering hereditary breast/ovarian cancer testing.
  • Clinical Exome Clinical exome sequencing panels for comprehensive detection of clinically significant variants, available in Standard (5,516 genes, 13.8 Mb) and Expanded (7,563 genes, 19.6 Mb) versions. Targeted at clinical diagnostics labs focused on inherited disease and rare disease variant detection.
  • PharmacoScreen Pharmacogenomics panel targeting genes associated with drug metabolism, available in Standard (283 genes, 634 Kb), Epilepsy (91 genes, 575.3 Kb), and Anti-Tuberculosis (132 genes, 186.1 Kb) configurations. Targeted at clinical labs, hospitals, and biopharma running pharmacogenomics-informed prescribing.
  • Disease Specific Panel Comprehensive panels for identification of 14–293 disease-related genes in a single NGS reaction with proven clinical usage, with target sizes ranging 37–1,159 Kb. Targeted at rare disease and inherited disorder diagnostic workflows.
  • RNA Sequencing Panel Targeted RNA sequencing solution for transcriptome, fusion, and isoform analyses, supported by the Celemics double-stranded cDNA synthesis kit. Targeted at research and translational labs needing validated targeted RNA capture.
  • Methylation Sequencing Panel Comprehensive DNA methylation sequencing solution with proprietary probes specifically designed for methyl-seq, enabling accurate detection of methylation sites for epigenetics research. Targeted at epigenetics research programs.
  • Metagenomic Sequencing Panel Complete targeted metagenomic sequencing solution with flexible panel design for characterization and differentiation of microbial species and bacterial pathogen detection. Targeted at infectious disease and microbiome research labs.
  • Mitochondrial DNA Panel High-uniformity, complete-coverage panel for human mitochondrial genome sequencing. Targeted at labs running mtDNA variant detection for inherited disease and population genetics research.
  • Respiratory Virus Panel Comprehensive panel for rapid and accurate sequencing and identification of whole genomes of 39 respiratory virus strains in a 706 Kb target. Targeted at public health labs and infectious disease surveillance programs.
  • African Swine Fever Virus Panel Accurate identification of various ASFV strains in a single NGS reaction with species-specific blockers, targeting 26 strains in a 192 Kb target. Targeted at veterinary and animal health surveillance programs.
  • High-Throughput Genotyping Panel NGS-based target enrichment panel for higher genotyping efficiency and accuracy in plant and animal research, providing a cost-effective solution compared to conventional GBS, PCR, and microarray methods. Targeted at agrigenomics research and breeding programs.
  • BioPharma Solutions End-to-end NGS-based detection and discovery solutions for biopharma companies, CROs, and drug discovery research fields, including companion diagnostics development, clinical trial support, drug discovery research, and pharmacogenomics panels. Targeted at biopharma and CRO drug development programs.
  • Celemics Analysis Service (CAS) End-to-end bioinformatics pipeline providing primary, secondary (CNV, Large InDel, TMB, MSI detection), and tertiary (variant curation, phenotype association) analysis with a click-to-upload FASTQ workflow and automated clinical interpretation report generation. Targeted at labs needing FASTQ-to-clinical-report processing without third-party bioinformaticians.
  • Immune Repertoire Profiling Service NGS-based BCR and TCR sequencing service with ultra-sensitivity MRD monitoring detecting MRD as low as 10⁻⁶, using optimized primers to minimize sequencing loss and PCR duplications. Targeted at immuno-oncology research and minimal residual disease studies.
  • Whole Exome Sequencing Service Full-service WES offering using the Celemics WES panel with complete bioinformatics analysis and clinical interpretation support. Targeted at research and clinical customers needing turnkey exome sequencing without in-house wet-lab or bioinformatics capacity.
  • High-Throughput Genotyping Service NGS-based target enrichment genotyping service delivering higher efficiency and accuracy than conventional GBS, PCR, and microarray methods for plant and animal research. Targeted at agrigenomics research groups and breeding programs.
  • Custom NGS Assay Development Tailored-fit assay development service covering custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, and validation runs to optimize individual experiments. Targeted at research and clinical customers needing non-standard or novel NGS assays.

Quantifiable outcome

  • WES panel achieves >98% coverage of all exonic regions of major exome panels (37.1 Mb target size)
  • +6 more outcomes

Companies that use Celemics

Customer profile

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Celemics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability4 records

Feature7 records

Celemics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Strand Life SciencescoreTechnology or Integration · 24 October 2024Strategic partnership integrating Celemics NGS target enrichment kit and bioinformatics pipeline with Strand Life Sciences' StrandOmics tertiary analysis platform. Provides seamless sample-to-report solution ensuring clinical-grade data compliance and guaranteed data residency for customers across Europe and Asia. Over 2.5 years of collaboration with Strand analyzing clinical cases including Whole Exome Sequencing for rare diseases, Hereditary Cancer Test, and OncoRisk Test for germline cancer with a 3-day turnaround time. Strand's expert variant scientists provided interpretation and review of over 30,000 variants.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Celemics competitors and assessment

Company assessment

Regional players

  • Eurofins Genomics: Eurofins Genomics operates one of the largest global genomics service networks, offering NGS panels, custom sequencing, and bioinformatics with strong European footprint. Eurofins competes with Celemics across clinical exome, rare disease, and biopharma sequencing services, particularly in European markets.
  • Azenta Life Sciences (GENEWIZ): Azenta/GENEWIZ is a major genomics services provider with global lab operations, offering NGS services including custom panels, WES, and bioinformatics. Azenta competes with Celemics' sequencing services and CAS bioinformatics offerings, particularly for biopharma customers seeking outsourcing alternatives to in-house capture workflows.

Direct peers

  • Integrated DNA Technologies (IDT): IDT, owned by Danaher, is a leading provider of NGS target enrichment solutions including xGen hybridization capture panels and Lockdown probes. IDT directly competes with Celemics in custom panel development and serves the same biopharma, clinical, and research customer base with overlapping catalog offerings.
  • Twist Bioscience: Twist Bioscience is the closest direct competitor to Celemics, offering DNA synthesis platforms and a comprehensive portfolio of NGS target enrichment panels and custom panels. Both companies compete in hybridization-based capture chemistry, custom panel development, and biopharma/CRO services, with Twist also pursuing the white-label/OEM model.

Broad incumbents

  • Agilent Technologies: Agilent's SureSelect target enrichment platform is the dominant hybridization capture chemistry in clinical and translational genomics. Agilent competes broadly with Celemics across whole-exome, custom panels, and biopharma services, with significantly greater installed base and clinical validation footprint.
  • Illumina: Illumina offers TruSeq, TruSight, and Illumina Exome panels as part of its sequencing platform ecosystem. While Illumina's capture chemistry is more limited than specialists, its bundling with the dominant sequencing platform creates competitive pressure on pure-play capture providers like Celemics, particularly in clinical genomics.
  • Roche (NimbleGen): Roche's NimbleGen SeqCap capture chemistry is a legacy target enrichment platform with a substantial installed base in academic and clinical genomics. Roche competes with Celemics in whole-exome and custom capture, particularly for translational and CDx applications tied to Roche's diagnostic franchise.
  • Bio-Techne: Bio-Techne's ProteinSimple and ExoDx brands include genomics-adjacent reagent and assay solutions. While Bio-Techne is more focused on proteomics, its life science tools portfolio competes for the same biopharma R&D budget and provides an alternative for reagent procurement in workflows adjacent to Celemics' products.

Emerging players

  • BGI Group / MGI Tech: BGI/MGI offers an integrated sequencing platform (DNBSEQ) along with capture chemistry and panels, and Celemics explicitly validates compatibility with MGI platforms. As MGI expands internationally, it represents both a partner opportunity and a competitive threat in the broader NGS ecosystem.

Others

  • Pacific Biosciences (PacBio): PacBio is a long-read sequencing platform provider with which Celemics has validated compatibility via instrument-specific blockers and assay optimization. PacBio represents both a partner (for Celemics' capture chemistry on HiFi platforms) and an indirect competitor as whole-genome HiFi sequencing reduces reliance on target enrichment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Celemics social profiles

Digital presence

Celemics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celemics leadership team

Management profile

Number of profiles

Profiles1 record

Celemics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Celemics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celemics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celemics

What does Celemics do?

Celemics designs, manufactures, and supplies hybridization-based Next-Generation Sequencing (NGS) target enrichment panels, custom assay development services, and end-to-end bioinformatics for genomics applications in oncology, inherited disease, biopharma/CRO drug discovery, pathogen surveillance, and agrigenomics. Its offering combines proprietary probe design and rebalancing technologies, molecular barcodes for low-input and cfDNA samples, ready-to-use and customized panels, modular reagents (library prep kits, beads, polymerases), and the Celemics Analysis Service (CAS) bioinformatics pipeline running from FASTQ through clinical interpretation.

Is Celemics a public or private company?

Celemics is a private company. It is classified as public and is currently operating.

When was Celemics founded?

Celemics was founded in 2010. It employs 11 to 50 people.

Where is Celemics based?

Celemics is headquartered in Seoul, South Korea, in the Asia region.

How does Celemics make money?

Five revenue lines are on record. NGS Panels and Reagents are the primary driver. The others are sequencing and Bioinformatics Services, custom NGS Assay Development, biopharma Solutions and Companion Diagnostics and white-Label / OEM Products.

Who are Celemics's main competitors?

Regional players on record are Eurofins Genomics and Azenta Life Sciences (GENEWIZ). Direct peers are Integrated DNA Technologies (IDT) and Twist Bioscience. Broad incumbents are Agilent Technologies, Illumina, Roche (NimbleGen) and Bio-Techne. BGI Group / MGI Tech is listed as an emerging player. Pacific Biosciences (PacBio) is listed as an others.

Does Celemics have an API?

No public API is recorded for Celemics.

What industry is Celemics in?

Celemics's product category is NGS Target Enrichment Reagents and Panels. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireCelemics, Establishes Foothold in U.S. Medicare Insurance Market Through Cancer Genomic Testing Collaboration with MCPTXCelemics announced a Memorandum of Understanding with MedCare Partners Health Plan of Texas to evaluate and potentially implement cancer genomic tests based on NGS. The collaboration covers hereditary, somatic, colorectal, breast, and lung cancer panels, aiming to secure insurance reimbursement and expand into Medicare and commercial insurers. Successful implementation could enable recurring revenue and rapid expansion across U.S. payers.VenturesquareSellemix secures 31 billion won in funding... Strengthening NGS core business and investing in new businesses, 'two-track' approach intensifies.CelemiX completed a 31 billion won fundraising round, including a 12 billion won private placement and prior convertible bonds. The company plans to use about 11.5 billion won for strategic investments and new business expansion. It aims to strengthen its NGS core business while pursuing new growth areas.PR NewswireCelemics liefert schnellere NGS-Datenerkenntnisse für Anreicherung von Zielregionen, entwickelt gemeinsam mit BlueBee globale Lösung für Genomik-DatenCelemics, a South Korean biotechnology company specializing in target enrichment kits for next-generation sequencing applications, announced a new comprehensive NGS workflow for clinical and translational research, developed in partnership with Dutch data platform provider BlueBee. The joint Celemics Web Solution integrates bioinformatics analysis capabilities designed to streamline the digital workflow aspect of target enrichment NGS testing, converting raw sequencing data into actionable results. BlueBee's platform enables Celemics to serve global markets with clinical regulatory compliance and guaranteed data residency for customers in Europe, Asia, and other regions.PR NewswireCelemics accélère les analyses de données NGS avec enrichissement ciblé en s'associant à BlueBee pour une solution de données génomiques mondialeCelemics, a South Korean provider of targeted enrichment kits for next-generation sequencing (NGS), announced a partnership with Dutch software company BlueBee to launch a comprehensive web-based workflow for targeted NGS enrichment in clinical and translational research. The integrated solution combines Celemics' enrichment kits with BlueBee's genomic data platform, enabling raw data to be transformed into actionable results while providing guaranteed data residency for clients in Europe, Asia, and globally. The collaboration aims to streamline data analysis bottlenecks and serve as a strategic extension to accelerate precision medicine initiatives worldwide.PR NewswireCelemics acelera el enriquecimiento de objetivos de visiones de datos NGS al asociarse con BlueBeeCelemics has partnered with BlueBee to integrate the BlueBee Genomics Platform into its NGS enrichment workflow, creating a unified web-based solution for clinical and translational research. This collaboration aims to accelerate precision medicine by providing standardized, high-performance data analysis tools for Celemics' global customer base in Europe and Asia.PR NewswireCelemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data SolutionCelemics, a South Korean biotech company specializing in NGS target enrichment kits, announced a strategic partnership with Netherlands-based bioinformatics provider BlueBee to launch an integrated end-to-end workflow solution for clinical and translational research. The Celemics web solution, built on BlueBee's genomics platform, provides standardized data analysis, clinical-grade data compliance, and guaranteed data residency for customers in Europe, Asia, and beyond. The partnership aims to accelerate precision medicine research by bridging wet-lab and data workflows, offering Celemics an extensible and scalable data strategy for global market expansion.